Evidence map›Paper›PMID 36771306›Full record

SynthesisNutrients2023

Effects of Glucomannan Supplementation on Type II Diabetes Mellitus in Humans: A Meta-Analysis.

Zhanzhi Zhang, Yu Zhang, Xiaomei Tao, Yuying Wang, Benqiang Rao, Hanping Shi

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhanzhi ZhangDepartment of General Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
Yu ZhangDepartment of VIP Medical Services, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Xiaomei TaoDepartment of Pharmacy, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
Yuying WangDepartment of General Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
Benqiang RaoDepartment of General Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
Hanping ShiKey Laboratory of Cancer FSMP for State Market Regulation, Beijing 100038, China.ORCID 0000-0003-4514-8693

Funding

Beijing Hospitals Authority Innovation Studio of Young Staff Funding Support 202115National Key Research and Development Program 2022YFC2009600National Natural Science Foundation of China 82074061
6 · The paper itself

Abstract

The hypoglycemic and lipid-lowering effects of glucomannan are widely known, and it is a potential effective treatment for type II diabetes. In this study, we evaluated the effects of glucomannan supplementation on blood-lipid-related indicators, blood-glucose-related indicators, blood pressure (BP), and body weight (BW) in patients suffering from type II diabetes. We searched databases including PubMed, Cochrane, the comprehensive biomedical research database (Embase), Web of Science, and China National Knowledge Infrastructure (CNKI) for literature on glucomannan and type II diabetes. Six randomized controlled trials (RCTs) were eligible (

Indexed as

Blood GlucoseDiabetes Mellitus, Type 2Dietary SupplementsHumansLipidsMannans(1-6)-alpha-glucomannanBlood GlucoseLipidsMannansglucomannanmeta-analysisnutritional interventionRCTstype II diabetes mellitus

Identifiers

PMID36771306
PMCPMC9919128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.